Flunixin meglumine antibody/antigen (BSA/OVA/KLH conjugated hapten)

 Download 

anti-Flunixin meglumine antibody and Carrier-coupled antigen/immunogen (hapten-carrier conjugates)

Go to Drugs of Abuse diagnostics products collection >>

Product information

Size： 1mg | 10mg | 100mg

Product Description

BSA-Flunixin meglumine

OVA-Flunixin meglumine

Anti-Flunixin meglumine mouse monoclonal antibody

Anti-Flunixin meglumine human monoclonal antibody

Reference

Data / case study

Click to get more Data / Case study about the product.

Biomarker Information

1. Flunixin Meglumine:



Flunixin meglumine, a potent non-steroidal anti-inflammatory drug (NSAID), is a small molecular compound that holds significant relevance in in vitro diagnostic (IVD) applications, particularly within the domain of veterinary medicine. Its classification as an NSAID underscores its therapeutic role in alleviating pain and inflammation in animals. In the context of IVD, Flunixin meglumine emerges as a critical target molecule for detection and quantitative analysis.

1.1. Molecular Structure and Characteristics:



Flunixin meglumine is chemically characterized as N-(2,6-dichloro-4-pyridyl)-3,5-dimethylbenzamine (CAS number: 38677-85-9). This compound presents as a white crystalline powder, which, when administered to animals, exerts its anti-inflammatory and analgesic effects. As a therapeutic agent, it is notably employed in veterinary practice to manage pain and inflammation in livestock, horses, and companion animals. In IVD applications, the precise quantification of Flunixin meglumine is of paramount importance, necessitating specialized tools and reagents.

1.2. Role in In Vitro Diagnosis (IVD):



In the IVD realm, our biopharmaceutical company offers a range of specific antibodies tailored to Flunixin meglumine. These antibodies are meticulously engineered to exhibit a high degree of selectivity, exclusively binding to Flunixin meglumine molecules. The primary purpose of these specialized antibodies is to facilitate the development of diagnostic assays that enable the accurate detection and quantification of Flunixin meglumine in a variety of sample matrices, including blood, tissue, and urine.

Within the veterinary field, these diagnostic assays empower veterinarians and researchers to monitor the presence and concentration of Flunixin meglumine in animal specimens. This capability, in turn, supports accurate diagnosis, treatment optimization, and therapeutic management of conditions where Flunixin meglumine is employed.

2. Rationale for Flunixin Meglumine Measurement:

2.1. Therapeutic Monitoring:

One of the primary motivations for measuring Flunixin meglumine levels is to enable therapeutic monitoring in veterinary medicine. This NSAID is widely used for its analgesic and anti-inflammatory properties, making it a crucial component in pain management and inflammation control in animals. By accurately quantifying Flunixin meglumine concentrations in the blood or tissue samples of treated animals, veterinarians can ensure that therapeutic levels are maintained. This is vital for optimizing treatment regimens and ensuring the well-being of animals undergoing pain and inflammation management.

2.2. Safety Assurance:

Accurate measurement of Flunixin meglumine levels is equally essential for ensuring the safety of animals. Administering the correct dosage is critical, as overdosing can lead to adverse effects. By continuously monitoring Flunixin meglumine concentrations, veterinarians can adjust dosages as needed, thereby preventing potential harm to animals. This aspect of safety is of paramount importance in veterinary medicine, where the well-being of animals is a top priority.

2.3. Scientific Research:

Beyond clinical applications, Flunixin meglumine serves as a subject of interest in scientific research. Pharmacokinetic and pharmacodynamic studies frequently require precise measurements of this NSAID. Researchers use these measurements to gain insights into its absorption, distribution, metabolism, and excretion (ADME) properties, as well as its mechanisms of action. This body of research contributes significantly to the understanding of Flunixin meglumine's effects and applications in veterinary medicine.

2.4. Regulatory Compliance:

Veterinary medicine operates within a framework of stringent regulations and guidelines. Adhering to these regulations is imperative to ensure the responsible use of Flunixin meglumine and other pharmaceutical agents in animal healthcare. Accurate measurement of Flunixin meglumine concentrations is essential to meet regulatory standards related to drug usage, safety, and efficacy in animals. Veterinarians and researchers must adhere to these standards to maintain the highest level of care and ethics in veterinary practice.

In conclusion, the measurement of Flunixin meglumine plays a multifaceted and indispensable role in veterinary medicine and scientific research. This significance is underpinned by its contributions to therapeutic monitoring, safety assurance, scientific inquiry, and regulatory compliance. Our biopharmaceutical company's specialized anti-Flunixin meglumine antibodies, along with competitive antigens, provide essential tools for the development of precise diagnostic assays, furthering the capabilities of veterinarians and researchers in the accurate assessment of this vital NSAID in animals.

About GDU